Yan Leyfman/LinkedIn
Apr 14, 2026, 13:09
Yan Leyfman: Rewriting Sickle Cell Disease Biology with CRISPR Technology
Yan Leyfman, Medical Oncologist, Co-Founder and Executive Director of MedNews Week, Medical Correspondent at OncLive, shared on LinkedIn:
”Thank you to Cancer Network for the feature.
Rewriting the Hemoglobin Switch: CRISPR Targeting in Sickle Cell Disease
Gene editing has moved from concept to clinic.
By leveraging CRISPR to reactivate fetal hemoglobin, we’re no longer just managing Sickle Cell Disease – we’re aiming to rewrite its biology.
Targeting regulators like BCL11A is elegant.
Making it durable, scalable, and accessible is the real challenge.
This is where curative intent becomes tangible.
Worth the read if you’re following where ‘hematology and gene therapy’ is heading.”
Stay updated with Hemostasis Today.
-
Jul 13, 2026, 13:2810 Posts Not To Miss from ISTH 2026, Part 2
-
Jul 13, 2026, 11:25Luisa Müller: Advancing Anticoagulation Strategies for VITT at ISTH 2026
-
Jul 13, 2026, 10:49Joshua Zeidner: Advancing Menin Inhibitor Therapy in MD Education AML-ALL US Focus 2026
-
Jul 13, 2026, 10:25Flora Peyvandi: A Practical Approach to ALT Elevation After Gene Therapy at ISTH 2026
-
Jul 13, 2026, 10:02Jessica Garcia: Where Science and Community Come Together at ISTH 2026
-
Jul 13, 2026, 09:46Fabrice Cognasse: Is There Such a Thing as the Perfect Platelet Product?
-
Jul 13, 2026, 09:42Cancer-Associated Arterial Thromboembolism: Redefining the Thrombotic Burden in Oncology
-
Jul 13, 2026, 05:59Connecting and Collaborating at ISTH 2026 – NNHF
-
Jul 13, 2026, 05:58Lara Monica: Back at ISTH – Looking Forward to Science and Reconnections!